SAN FRANCISCO--(BUSINESS WIRE)--Counsyl, a health technology company that offers DNA testing for diseases that can impact men, women and their children, today announced that it will be presenting four scientific posters and an educational speaker series at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, which will be held March 8-12, 2016 in Tampa, Florida.
Counsyl will share data, synthesized from over half a million DNA screens, through a series of posters and educational presentations, including two top rated posters highlighting the actions couples choose to take with expanded carrier screen results and in addition, how to calculate individualized PPV in order to clarify true risk in non-invasive prenatal screening.
For more information on Counsyl at the ACMG Annual Clinical Genetics Meeting, visit booth #715 or acmg2016.counsyl.com. The titles and schedules of the talks and poster presentations are as follows:
Wednesday March 9
- Concurrent session, 10:00 AM - Where are the patients? Discrepancies between carrier frequencies & birth incidence
Thursday March 10
- Oral abstract #12, 8:00 AM - An online results delivery and counseling system may increase access to hereditary cancer testing and genetic counseling
- Oral abstract #3, 8:45 AM - The Hexosaminidase A Variants of Unknown Significance (HAVUS) classification project
- Poster #601 (top rated), 10:30 AM - Clinical utility of expanded carrier screening: Reproductive behaviors of at-risk carrier couples
- Poster #599 (top rated), 10:30 AM - Putting guidelines into action: accurate computation of positive predictive value (PPV) for aneuploidy screening in cell-free DNA
- Poster #649, 10:30 AM - When cost is no barrier: uptake in a metropolitan area free inherited cancer screening program
- Poster #229, 10:30 AM - Genomic variant annotation using semi-supervised clustering outperforms existing consensus and variant-type-specific methods
Friday March 11
- Poster #418, 10:30 AM - Design of scalable gene panel for carrier screening
- Poster #630, 10:30 AM - Design and validation of an improved non-invasive prenatal screen for fetal aneuploidy
About Counsyl
Counsyl is a health technology company that offers DNA testing for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
The Counsyl team includes an accomplished group of problem-solvers — top engineers, scientists, and designers — who are taking the lead on building the modern clinical laboratory. Scientific rigor, custom robotics, and software are at the heart of every Counsyl product, resulting in better, faster and more affordable screens that are broadly accessible. Beyond the laboratory, Counsyl offers doctors and patients a technology platform for results delivery in real time, with on-demand access to board-certified genetic counselors. Counsyl has screened more than 500,000 patients and served more than 6,000 health care professionals in its CLIA-certified, CAP-accredited and NYS CLEP-permitted clinical laboratory.